Research ArticleParkinson’s Disease
A cullin-RING ubiquitin ligase targets exogenous α-synuclein and inhibits Lewy body–like pathology
- Juan A. Gerez1,2,*,
- Natalia C. Prymaczok1,2,
- Edward Rockenstein3,
- Uli S. Herrmann4,
- Petra Schwarz4,
- Anthony Adame3,
- Radoslav I. Enchev1,†,
- Thibault Courtheoux1,
- Paul J. Boersema1,‡,
- Roland Riek2,
- Matthias Peter1,
- Adriano Aguzzi4,
- Eliezer Masliah3§ and
- Paola Picotti1,5
- 1Institute of Biochemistry, Department of Biology, ETH Zurich, CH-8093 Zurich, Switzerland.
- 2Laboratory of Physical Chemistry, Department of Chemistry and Applied Biosciences, ETH Zurich, CH-8093 Zurich, Switzerland.
- 3Department of Neurosciences, University of California, San Diego, La Jolla, San Diego, CA 92093, USA.
- 4Institute of Neuropathology, University Hospital Zurich, Zurich CH-8091, Switzerland.
- 5Institute of Molecular Systems Biology, Department of Biology, ETH Zurich, CH-8093 Zurich, Switzerland.
- ↵*Corresponding author. Email: juan.gerez{at}phys.chem.ethz.ch
↵† Present address: The Francis Crick Institute, Visual Biochemistry Laboratory, London, UK.
↵‡ Present address: Novartis Pharma AG, Basel, Switzerland.
§ Present address: Laboratory of Neurogenetics and Division of Neuroscience, National Institute on Aging, NIH, Bethesda, MD, USA.
See allHide authors and affiliations
Science Translational Medicine 05 Jun 2019:
Vol. 11, Issue 495, eaau6722
DOI: 10.1126/scitranslmed.aau6722
